{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:53:32Z","timestamp":1791348812714,"version":"4.3.1"},"reference-count":118,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Institute for Healt Research (NIHR) Biomedical Research Centre"},{"name":"UCL Institute of Ophthalmology"},{"DOI":"10.13039\/501100000615","name":"Fight for Sight UK","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000615","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Moorfields Eye Charity"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.exer.2017.01.001","type":"journal-article","created":{"date-parts":[[2017,1,6]],"date-time":"2017-01-06T17:49:54Z","timestamp":1483724994000},"page":"24-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Mechanism and evidence of nonsense suppression therapy for genetic eye disorders"],"prefix":"10.1016","volume":"155","author":[{"given":"Rose","family":"Richardson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Smart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhani","family":"Tracey-White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariya","family":"Moosajee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7013","key":"10.1016\/j.exer.2017.01.001_bib1","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03060","article-title":"A\u00a0faux 3'-UTR promotes aberrant termination and triggers nonsense-mediated mRNA decay","volume":"432","author":"Amrani","year":"2004","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.exer.2017.01.001_bib2","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.febslet.2013.05.020","article-title":"The cell stress machinery and retinal degeneration","volume":"587","author":"Athanasiou","year":"2013","journal-title":"FEBS Lett."},{"issue":"9","key":"10.1016\/j.exer.2017.01.001_bib3","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1073\/pnas.0813345106","article-title":"Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression","volume":"106","author":"Auld","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.exer.2017.01.001_bib4","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/nm1197-1280","article-title":"Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line","volume":"3","author":"Bedwell","year":"1997","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.exer.2017.01.001_bib5","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.molmed.2012.09.004","article-title":"Cancer syndromes and therapy by stop-codon readthrough","volume":"18","author":"Bordeira-Carrico","year":"2012","journal-title":"Trends Mol. Med."},{"issue":"3","key":"10.1016\/j.exer.2017.01.001_bib6","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/mt.2012.280","article-title":"A\u00a0comprehensive review of retinal gene therapy","volume":"21","author":"Boye","year":"2013","journal-title":"Mol. Ther."},{"issue":"13","key":"10.1016\/j.exer.2017.01.001_bib7","doi-asserted-by":"crossref","first-page":"8232","DOI":"10.1167\/iovs.12-11025","article-title":"Mutations in RPGR and RP2 account for 15% of males with simplex retinal degenerative disease","volume":"53","author":"Branham","year":"2012","journal-title":"Invest Ophthalmol. Vis. Sci."},{"issue":"4","key":"10.1016\/j.exer.2017.01.001_bib8","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mus.24332","article-title":"Ataluren treatment of patients with nonsense mutation dystrophinopathy","volume":"50","author":"Bushby","year":"2014","journal-title":"Muscle & Nerve"},{"key":"10.1016\/j.exer.2017.01.001_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2199-2-3","article-title":"UAG readthrough in mammalian cells: effect of upstream and downstream stop codon contexts reveal different signals","volume":"2","author":"Cassan","year":"2001","journal-title":"BMC Mol. Biol."},{"key":"10.1016\/j.exer.2017.01.001_bib10","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.biochi.2014.10.027","article-title":"NMD: at the crossroads between translation termination and ribosome recycling","volume":"114","author":"Celik","year":"2014","journal-title":"Biochimie"},{"issue":"1","key":"10.1016\/j.exer.2017.01.001_bib11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1023\/A:1023474719042","article-title":"Comparison of cytotoxicity of aminoglycoside antibiotics using a panel cellular biotest system","volume":"135","author":"Chernikov","year":"2003","journal-title":"Bull. Exp. Biol. Med."},{"issue":"6","key":"10.1016\/j.exer.2017.01.001_bib12","doi-asserted-by":"crossref","first-page":"E517","DOI":"10.1073\/pnas.1218933110","article-title":"Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement","volume":"110","author":"Cideciyan","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.exer.2017.01.001_bib13","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/archopht.1995.01100070025016","article-title":"SUccessful prevention of visual loss with emergency management following inadvertent intracameral injection of gentamicin","volume":"113","author":"Daily","year":"1995","journal-title":"Archives Ophthalmol."},{"issue":"7","key":"10.1016\/j.exer.2017.01.001_bib14","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00109-006-0045-5","article-title":"Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model","volume":"84","author":"Du","year":"2006","journal-title":"J.\u00a0Mol. Med. Berl."},{"issue":"6","key":"10.1016\/j.exer.2017.01.001_bib15","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1073\/pnas.0711795105","article-title":"PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model","volume":"105","author":"Du","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.exer.2017.01.001_bib16","doi-asserted-by":"crossref","first-page":"6885","DOI":"10.1074\/jbc.M806728200","article-title":"Poly-L-aspartic acid enhances and prolongs gentamicin-mediated suppression of the CFTR-G542X mutation in a cystic fibrosis mouse model","volume":"284","author":"Du","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"issue":"10","key":"10.1016\/j.exer.2017.01.001_bib17","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1084\/jem.20081940","article-title":"Nonaminoglycoside compounds induce readthrough of nonsense mutations","volume":"206","author":"Du","year":"2009","journal-title":"J.\u00a0Exp. Med."},{"issue":"9","key":"10.1016\/j.exer.2017.01.001_bib18","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1038\/mt.2013.150","article-title":"A\u00a0new series of small molecular weight compounds induce read through of all three types of nonsense mutations in the ATM gene","volume":"21","author":"Du","year":"2013","journal-title":"Mol. Ther."},{"issue":"7","key":"10.1016\/j.exer.2017.01.001_bib19","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.cell.2014.04.033","article-title":"Programmed translational readthrough generates anti-angiogenic VEGF-ax","volume":"157","author":"Eswarappa","year":"2014","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.exer.2017.01.001_bib20","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1261\/rna.805208","article-title":"Eukaryotic ribosomal RNA determinants of aminoglycoside resistance and their role in translational fidelity","volume":"14","author":"Fan-Minogue","year":"2008","journal-title":"RNA"},{"issue":"10","key":"10.1016\/j.exer.2017.01.001_bib21","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1261\/rna.044933.114","article-title":"The interaction of cytoplasmic poly(A)-binding protein with eukaryotic initiation factor 4G suppresses nonsense-mediated mRNA decay","volume":"20","author":"Fatscher","year":"2014","journal-title":"RNA"},{"issue":"11","key":"10.1016\/j.exer.2017.01.001_bib22","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1023\/A:1011925132473","article-title":"Altered tissue distribution and elimination of amikacin encapsulated in unilamellar, low-clearance liposomes (MiKasome)","volume":"15","author":"Fielding","year":"1998","journal-title":"Pharm. Res."},{"issue":"9","key":"10.1016\/j.exer.2017.01.001_bib23","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1177\/0883073810371129","article-title":"Read-through strategies for suppression of nonsense mutations in Duchenne\/Becker muscular dystrophy: aminoglycosides and ataluren (PTC124)","volume":"25","author":"Finkel","year":"2010","journal-title":"J.\u00a0Child. Neurol."},{"issue":"12","key":"10.1016\/j.exer.2017.01.001_bib24","doi-asserted-by":"crossref","first-page":"e81302","DOI":"10.1371\/journal.pone.0081302","article-title":"Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy","volume":"8","author":"Finkel","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.exer.2017.01.001_bib25","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/00006982-199807000-00008","article-title":"Intraocular penetration of gentamicin after once-daily aminoglycoside dosing","volume":"18","author":"Fiscella","year":"1998","journal-title":"Retina"},{"issue":"8","key":"10.1016\/j.exer.2017.01.001_bib26","doi-asserted-by":"crossref","first-page":"e24125","DOI":"10.1371\/journal.pone.0024125","article-title":"Readthrough of premature termination codons in the adenomatous polyposis coli gene restores its biological activity in human cancer cells","volume":"6","author":"Floquet","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.exer.2017.01.001_bib27","doi-asserted-by":"crossref","first-page":"e1002608","DOI":"10.1371\/journal.pgen.1002608","article-title":"Statistical analysis of readthrough levels for nonsense mutations in mammalian cells reveals a major determinant of response to gentamicin","volume":"8","author":"Floquet","year":"2012","journal-title":"PLoS Genet."},{"issue":"10","key":"10.1016\/j.exer.2017.01.001_bib28","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1093\/hmg\/8.10.1893","article-title":"Nonsense-mediated mRNA decay in health and disease","volume":"8","author":"Frischmeyer","year":"1999","journal-title":"Hum. Mol. Genet."},{"issue":"4","key":"10.1016\/j.exer.2017.01.001_bib29","first-page":"334","article-title":"Eukaryotic polypeptide chain release factor eRF3 is an eRF1- and ribosome-dependent guanosine triphosphatase","volume":"2","author":"Frolova","year":"1996","journal-title":"Rna"},{"issue":"12","key":"10.1016\/j.exer.2017.01.001_bib30","doi-asserted-by":"crossref","first-page":"6671","DOI":"10.1167\/iovs.10-5741","article-title":"Beneficial read-through of a USH1C nonsense mutation by designed aminoglycoside NB30 in the retina","volume":"51","author":"Goldmann","year":"2010","journal-title":"Invest Ophthalmol. Vis. Sci."},{"issue":"5","key":"10.1016\/j.exer.2017.01.001_bib31","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1089\/hum.2010.067","article-title":"PTC124-mediated translational readthrough of a nonsense mutation causing Usher syndrome type 1C","volume":"22","author":"Goldmann","year":"2011","journal-title":"Hum. Gene Ther."},{"issue":"11","key":"10.1016\/j.exer.2017.01.001_bib32","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/emmm.201201438","article-title":"A\u00a0comparative evaluation of NB30, NB54 and PTC124 in translational read-through efficacy for treatment of an USH1C nonsense mutation","volume":"4","author":"Goldmann","year":"2012","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.exer.2017.01.001_bib33","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1750-1172-7-58","article-title":"Rescue of nonsense mutations by amlexanox in human cells","volume":"7","author":"Gonzalez-Hilarion","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.exer.2017.01.001_bib34","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1750-1172-7-58","article-title":"Rescue of nonsense mutations by amlexanox in human cells","volume":"7","author":"Gonzalez-Hilarion","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.exer.2017.01.001_bib35","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/jmg.39.1.62","article-title":"In\u00a0vitro analysis of aminoglycoside therapy for the Arg120stop nonsense mutation in RP2 patients","volume":"39","author":"Grayson","year":"2002","journal-title":"J.\u00a0Med. Genet."},{"issue":"1","key":"10.1016\/j.exer.2017.01.001_bib36","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1172\/JCI70462","article-title":"Postnatal manipulation of Pax6 dosage reverses congenital tissue malformation defects","volume":"124","author":"Gregory-Evans","year":"2014","journal-title":"J.\u00a0Clin. Invest"},{"issue":"9","key":"10.1016\/j.exer.2017.01.001_bib37","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/archopht.1990.01070110022002","article-title":"AMinoglycoside macular toxicity after subconjunctival injection","volume":"108","author":"Grizzard","year":"1990","journal-title":"Archives Ophthalmol."},{"issue":"3","key":"10.1016\/j.exer.2017.01.001_bib38","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.exer.2008.05.016","article-title":"Systemic aminoglycoside treatment in rodent models of retinitis pigmentosa","volume":"87","author":"Guerin","year":"2008","journal-title":"Exp. Eye Res."},{"issue":"2","key":"10.1016\/j.exer.2017.01.001_bib39","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1039\/B712690P","article-title":"Designer aminoglycosides: the race to develop improved antibiotics and compounds for the treatment of human genetic diseases","volume":"6","author":"Hainrichson","year":"2008","journal-title":"Org. Biomol. Chem."},{"issue":"12","key":"10.1016\/j.exer.2017.01.001_bib40","doi-asserted-by":"crossref","first-page":"4804","DOI":"10.1167\/iovs.05-0604","article-title":"Acute aminoglycoside retinal toxicity in\u00a0vivo and in\u00a0vitro","volume":"46","author":"Hancock","year":"2005","journal-title":"Invest Ophthalmol. Vis. Sci."},{"issue":"4","key":"10.1016\/j.exer.2017.01.001_bib41","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1086\/302325","article-title":"Mutations in the RP2 gene cause disease in 10% of families with familial X-linked retinitis pigmentosa assessed in this study","volume":"64","author":"Hardcastle","year":"1999","journal-title":"Am. J. Hum. Genet."},{"issue":"6","key":"10.1016\/j.exer.2017.01.001_bib42","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1167\/iovs.08-2827","article-title":"Detailed ophthalmologic evaluation of 43 individuals with PAX6 mutations","volume":"50","author":"Hingorani","year":"2009","journal-title":"Invest Ophthalmol. Vis. Sci."},{"issue":"4","key":"10.1016\/j.exer.2017.01.001_bib43","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1177\/0091270006297140","article-title":"Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers","volume":"47","author":"Hirawat","year":"2007","journal-title":"J.\u00a0Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.exer.2017.01.001_bib44","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0161-6420(99)00140-2","article-title":"Visual acuity in children with coloboma: clinical features and a new phenotypic classification system","volume":"107","author":"Hornby","year":"2000","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.exer.2017.01.001_bib45","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/emboj.2008.17","article-title":"Interactions between UPF1, eRFs, PABP and the exon junction complex suggest an integrated model for mammalian NMD pathways","volume":"27","author":"Ivanov","year":"2008","journal-title":"EMBO J."},{"issue":"23","key":"10.1016\/j.exer.2017.01.001_bib46","doi-asserted-by":"crossref","first-page":"10630","DOI":"10.1021\/jm3012992","article-title":"Increased selectivity toward cytoplasmic versus mitochondrial ribosome confers improved efficiency of synthetic aminoglycosides in fixing damaged genes: a strategy for treatment of genetic diseases caused by nonsense mutations","volume":"55","author":"Kandasamy","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"issue":"2","key":"10.1016\/j.exer.2017.01.001_bib47","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ymthe.2003.11.020","article-title":"Antioxidant gene therapy can protect hearing and hair cells from ototoxicity","volume":"9","author":"Kawamoto","year":"2004","journal-title":"Mol. Ther."},{"issue":"18","key":"10.1016\/j.exer.2017.01.001_bib48","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1093\/hmg\/dds223","article-title":"Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy","volume":"21","author":"Kayali","year":"2012","journal-title":"Hum. Mol. Genet."},{"issue":"6","key":"10.1016\/j.exer.2017.01.001_bib49","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00109-001-0317-z","article-title":"Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system","volume":"80","author":"Keeling","year":"2002","journal-title":"J.\u00a0Mol. Med. Berl."},{"issue":"6","key":"10.1016\/j.exer.2017.01.001_bib50","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/wrna.95","article-title":"Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases","volume":"2","author":"Keeling","year":"2011","journal-title":"Wiley Interdiscip. Rev. RNA"},{"issue":"3","key":"10.1016\/j.exer.2017.01.001_bib51","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/hmg\/10.3.291","article-title":"Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation","volume":"10","author":"Keeling","year":"2001","journal-title":"Hum. Mol. Genet."},{"issue":"5","key":"10.1016\/j.exer.2017.01.001_bib52","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3109\/10409238.2012.694846","article-title":"Suppression of premature termination codons as a therapeutic approach","volume":"47","author":"Keeling","year":"2012","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"issue":"9640","key":"10.1016\/j.exer.2017.01.001_bib53","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(08)61168-X","article-title":"Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial","volume":"372","author":"Kerem","year":"2008","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.exer.2017.01.001_bib54","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S2213-2600(14)70100-6","article-title":"Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial","volume":"2","author":"Kerem","year":"2014","journal-title":"Lancet Respir. Med."},{"issue":"3","key":"10.1016\/j.exer.2017.01.001_bib55","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/00016480701558948","article-title":"Comparisons of cochleotoxicity among three gentamicin compounds following intratympanic application","volume":"128","author":"Kobayashi","year":"2008","journal-title":"Acta Otolaryngol."},{"issue":"14","key":"10.1016\/j.exer.2017.01.001_bib56","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/cbic.200700271","article-title":"Differential selectivity of natural and synthetic aminoglycosides towards the eukaryotic and prokaryotic decoding A sites","volume":"8","author":"Kondo","year":"2007","journal-title":"Chembiochem"},{"issue":"17","key":"10.1016\/j.exer.2017.01.001_bib57","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.1093\/emboj\/20.17.4987","article-title":"The exon-exon junction complex provides a binding platform for factors involved in mRNA export and nonsense-mediated mRNA decay","volume":"20","author":"Le Hir","year":"2001","journal-title":"EMBO J."},{"issue":"2","key":"10.1016\/j.exer.2017.01.001_bib58","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.pharmthera.2012.07.007","article-title":"Pharmaceutical therapies to recode nonsense mutations in inherited diseases","volume":"136","author":"Lee","year":"2012","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.exer.2017.01.001_bib59","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1021\/mp400230s","article-title":"Toward a rationale for the PTC124 (Ataluren) promoted readthrough of premature stop codons: a computational approach and GFP-reporter cell-based assay","volume":"11","author":"Lentini","year":"2014","journal-title":"Mol. Pharm."},{"issue":"4","key":"10.1016\/j.exer.2017.01.001_bib60","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1096\/fj.13-240044","article-title":"Muscle dysfunction and structural defects of dystrophin-null sapje mutant zebrafish larvae are rescued by ataluren treatment","volume":"28","author":"Li","year":"2014","journal-title":"FASEB J."},{"issue":"11","key":"10.1016\/j.exer.2017.01.001_bib61","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.tig.2008.08.010","article-title":"Introducing sense into nonsense in treatments of human genetic diseases","volume":"24","author":"Linde","year":"2008","journal-title":"Trends Genet."},{"issue":"3","key":"10.1016\/j.exer.2017.01.001_bib62","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1172\/JCI28523","article-title":"Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin","volume":"117","author":"Linde","year":"2007","journal-title":"J.\u00a0Clin. Invest"},{"issue":"5","key":"10.1016\/j.exer.2017.01.001_bib63","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1006\/jmbi.2000.4419","article-title":"Structure of a eukaryotic decoding region A-site RNA","volume":"306","author":"Lynch","year":"2001","journal-title":"J.\u00a0Mol. Biol."},{"issue":"9923","key":"10.1016\/j.exer.2017.01.001_bib64","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(13)62117-0","article-title":"Retinal gene therapy in patients with choroideremia: initial findings from a phase 1\/2 clinical trial","volume":"383","author":"MacLaren","year":"2014","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.exer.2017.01.001_bib65","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/1756285610388693","article-title":"Aminoglycoside-induced mutation suppression (stop codon readthrough) as a therapeutic strategy for Duchenne muscular dystrophy","volume":"3","author":"Malik","year":"2010","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"6","key":"10.1016\/j.exer.2017.01.001_bib66","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ana.22024","article-title":"Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy","volume":"67","author":"Malik","year":"2010","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.exer.2017.01.001_bib67","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1017\/S1355838200000716","article-title":"Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system","volume":"6","author":"Manuvakhova","year":"2000","journal-title":"RNA"},{"issue":"3","key":"10.1016\/j.exer.2017.01.001_bib68","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1242\/dev.055178","article-title":"Combinatorial regulation of optic cup progenitor cell fate by SOX2 and PAX6","volume":"138","author":"Matsushima","year":"2011","journal-title":"Development"},{"issue":"12","key":"10.1016\/j.exer.2017.01.001_bib69","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1073\/pnas.92.12.5431","article-title":"Translational termination efficiency in mammals is influenced by the base following the stop codon","volume":"92","author":"McCaughan","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.exer.2017.01.001_bib70","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0161-6420(86)33648-0","article-title":"Retinal toxicity secondary to intraocular gentamicin injection","volume":"93","author":"McDonald","year":"1986","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2017.01.001_bib71","first-page":"650","article-title":"Nonsense mutation in TMEM126A causing autosomal recessive optic atrophy and auditory neuropathy","volume":"16","author":"Meyer","year":"2010","journal-title":"Mol. Vis."},{"issue":"3","key":"10.1016\/j.exer.2017.01.001_bib72","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1172\/JCI118176","article-title":"Evidence that epithelial glycoprotein 330\/megalin mediates uptake of polybasic drugs","volume":"96","author":"Moestrup","year":"1995","journal-title":"J.\u00a0Clin. Invest"},{"issue":"24","key":"10.1016\/j.exer.2017.01.001_bib73","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1093\/hmg\/ddn302","article-title":"Translational bypass of nonsense mutations in zebrafish rep1, pax2.1 and lamb1 highlights a viable therapeutic option for untreatable genetic eye disease","volume":"17","author":"Moosajee","year":"2008","journal-title":"Hum. Mol. Genet."},{"issue":"6","key":"10.1016\/j.exer.2017.01.001_bib74","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1167\/iovs.08-2755","article-title":"Single choroideremia gene in nonmammalian vertebrates explains early embryonic lethality of the zebrafish model of choroideremia","volume":"50","author":"Moosajee","year":"2009","journal-title":"Invest Ophthalmol. Vis. Sci."},{"issue":"4","key":"10.1016\/j.exer.2017.01.001_bib75","doi-asserted-by":"crossref","DOI":"10.1038\/ejhg.2013.183","article-title":"Clinical utility gene card for: choroideremia","volume":"22","author":"Moosajee","year":"2014","journal-title":"Eur. J. Hum. Genet."},{"issue":"16","key":"10.1016\/j.exer.2017.01.001_bib76","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1093\/hmg\/ddw184","article-title":"Functional rescue of REP1 following treatment with PTC124 and novel derivative PTC-414 in human choroideremia fibroblasts and the nonsense-mediated zebrafish model","volume":"25","author":"Moosajee","year":"2016","journal-title":"Hum. Mol. Genet."},{"issue":"4\u20135","key":"10.1016\/j.exer.2017.01.001_bib77","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1017\/S0952523814000194","article-title":"Translational read-through as an alternative approach for ocular gene therapy of retinal dystrophies caused by in-frame nonsense mutations","volume":"31","author":"Nagel-Wolfrum","year":"2014","journal-title":"Vis. Neurosci."},{"issue":"2","key":"10.1016\/j.exer.2017.01.001_bib78","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s40259-016-0157-6","article-title":"Targeting nonsense mutations in diseases with translational read-through-inducing drugs (TRIDs)","volume":"30","author":"Nagel-Wolfrum","year":"2016","journal-title":"BioDrugs"},{"issue":"9","key":"10.1016\/j.exer.2017.01.001_bib79","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/embo-reports\/kve176","article-title":"Impact of the six nucleotides downstream of the stop codon on translation termination","volume":"2","author":"Namy","year":"2001","journal-title":"EMBO Rep."},{"issue":"24","key":"10.1016\/j.exer.2017.01.001_bib80","doi-asserted-by":"crossref","first-page":"6310","DOI":"10.1016\/j.bmcl.2006.09.013","article-title":"Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations","volume":"16","author":"Nudelman","year":"2006","journal-title":"Bioorg Med. Chem. Lett."},{"issue":"9","key":"10.1016\/j.exer.2017.01.001_bib81","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1021\/jm801640k","article-title":"Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations","volume":"52","author":"Nudelman","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"issue":"11","key":"10.1016\/j.exer.2017.01.001_bib82","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1016\/j.bmc.2010.03.060","article-title":"Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations","volume":"18","author":"Nudelman","year":"2010","journal-title":"Bioorg Med. Chem."},{"issue":"13","key":"10.1016\/j.exer.2017.01.001_bib83","doi-asserted-by":"crossref","first-page":"6528","DOI":"10.1093\/nar\/gkv588","article-title":"Resistance of mRNAs with AUG-proximal nonsense mutations to nonsense-mediated decay reflects variables of mRNA structure and translational activity","volume":"43","author":"Pereira","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"10","key":"10.1016\/j.exer.2017.01.001_bib84","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/cbic.200300657","article-title":"The molecular basis for A-site mutations conferring aminoglycoside resistance: relationship between ribosomal susceptibility and X-ray crystal structures","volume":"4","author":"Pfister","year":"2003","journal-title":"Chembiochem"},{"key":"10.1016\/j.exer.2017.01.001_bib85","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ejmech.2015.06.038","article-title":"Enhancement of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives","volume":"101","author":"Pibiri","year":"2015","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.exer.2017.01.001_bib86","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.cell.2004.05.017","article-title":"Structure of the Rab7:REP-1 complex: insights into the mechanism of Rab prenylation and choroideremia disease","volume":"117","author":"Rak","year":"2004","journal-title":"Cell"},{"issue":"3\u20134","key":"10.1016\/j.exer.2017.01.001_bib87","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00439-007-0410-7","article-title":"In\u00a0vitro and ex\u00a0vivo suppression by aminoglycosides of PCDH15 nonsense mutations underlying type 1 Usher syndrome","volume":"122","author":"Rebibo-Sabbah","year":"2007","journal-title":"Hum. Genet."},{"key":"10.1016\/j.exer.2017.01.001_bib88","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/0-387-32442-9_49","article-title":"Molecular analysis of the supramolecular usher protein complex in the retina. Harmonin as the key protein of the Usher syndrome","volume":"572","author":"Reiners","year":"2006","journal-title":"Adv. Exp. Med. Biol."},{"issue":"1","key":"10.1016\/j.exer.2017.01.001_bib89","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.exer.2005.11.010","article-title":"Molecular basis of human Usher syndrome: deciphering the meshes of the Usher protein network provides insights into the pathomechanisms of the Usher disease","volume":"83","author":"Reiners","year":"2006","journal-title":"Exp. Eye Res."},{"issue":"11","key":"10.1016\/j.exer.2017.01.001_bib90","doi-asserted-by":"crossref","DOI":"10.1038\/ejhg.2016.73","article-title":"Clinical utility gene card for: Aniridia","volume":"24","author":"Richardson","year":"2016","journal-title":"Eur. J. Hum. Genet."},{"issue":"4","key":"10.1016\/j.exer.2017.01.001_bib92","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.febslet.2004.11.048","article-title":"Recognition and selection of tRNA in translation","volume":"579","author":"Rodnina","year":"2005","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.exer.2017.01.001_bib93","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ajhg.2013.05.005","article-title":"Mutations in RAB28, encoding a farnesylated small GTPase, are associated with autosomal-recessive cone-rod dystrophy","volume":"93","author":"Roosing","year":"2013","journal-title":"Am. J. Hum. Genet."},{"issue":"11","key":"10.1016\/j.exer.2017.01.001_bib94","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s00109-011-0787-6","article-title":"Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54","volume":"89","author":"Rowe","year":"2011","journal-title":"J.\u00a0Mol. Med. Berl."},{"issue":"44","key":"10.1016\/j.exer.2017.01.001_bib95","doi-asserted-by":"crossref","first-page":"12508","DOI":"10.1073\/pnas.1605336113","article-title":"Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression","volume":"113","author":"Roy","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"14","key":"10.1016\/j.exer.2017.01.001_bib96","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s40265-014-0287-4","article-title":"Ataluren: first global approval","volume":"74","author":"Ryan","year":"2014","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.exer.2017.01.001_bib97","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/WCO.0b013e3283218807","article-title":"Update on usher syndrome","volume":"22","author":"Saihan","year":"2009","journal-title":"Curr. Opin. Neurol."},{"issue":"17","key":"10.1016\/j.exer.2017.01.001_bib98","doi-asserted-by":"crossref","first-page":"7769","DOI":"10.1128\/MCB.24.17.7769-7778.2004","article-title":"GTP hydrolysis by eRF3 facilitates stop codon decoding during eukaryotic translation termination","volume":"24","author":"Salas-Marco","year":"2004","journal-title":"Mol. Cell Biol."},{"issue":"10","key":"10.1016\/j.exer.2017.01.001_bib99","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1681\/ASN.2005101124","article-title":"A\u00a0non-nephrotoxic gentamicin congener that retains antimicrobial efficacy","volume":"17","author":"Sandoval","year":"2006","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.exer.2017.01.001_bib100","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/jac\/48.3.333","article-title":"Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies","volume":"48","author":"Schiffelers","year":"2001","journal-title":"J.\u00a0Antimicrob. Chemother."},{"issue":"4","key":"10.1016\/j.exer.2017.01.001_bib101","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/hmg\/ddu509","article-title":"Translational read-through of the RP2 Arg120stop mutation in patient iPSC-derived retinal pigment epithelium cells","volume":"24","author":"Schwarz","year":"2014","journal-title":"Hum. Mol. Genet."},{"issue":"10","key":"10.1016\/j.exer.2017.01.001_bib102","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1164\/rccm.201001-0137OC","article-title":"Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis","volume":"182","author":"Sermet-Gaudelus","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.exer.2017.01.001_bib103","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1074\/jbc.M113.533588","article-title":"Designer aminoglycosides that selectively inhibit cytoplasmic rather than mitochondrial ribosomes show decreased ototoxicity: a strategy for the treatment of genetic diseases","volume":"289","author":"Shulman","year":"2014","journal-title":"J.\u00a0Biol. Chem."},{"issue":"3","key":"10.1016\/j.exer.2017.01.001_bib104","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1261\/rna.815108","article-title":"Proximity of the poly(A)-binding protein to a premature termination codon inhibits mammalian nonsense-mediated mRNA decay","volume":"14","author":"Silva","year":"2008","journal-title":"RNA"},{"issue":"4","key":"10.1016\/j.exer.2017.01.001_bib105","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1371\/journal.pbio.0060111","article-title":"A\u00a0competition between stimulators and antagonists of Upf complex recruitment governs human nonsense-mediated mRNA decay","volume":"6","author":"Singh","year":"2008","journal-title":"PLoS Biol."},{"key":"10.1016\/j.exer.2017.01.001_bib106","first-page":"e34406","article-title":"Proteins involved in the degradation of cytoplasmic mRNA in the major eukaryotic model systems","author":"Siwaszek","year":"2014","journal-title":"RNA Biol."},{"issue":"9","key":"10.1016\/j.exer.2017.01.001_bib107","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.1128\/JVI.73.9.7812-7816.1999","article-title":"Rescue from photoreceptor degeneration in the rd mouse by human immunodeficiency virus vector-mediated gene transfer","volume":"73","author":"Takahashi","year":"1999","journal-title":"J.\u00a0Virol."},{"issue":"5","key":"10.1016\/j.exer.2017.01.001_bib108","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1128\/AAC.38.5.1027","article-title":"Attenuation by daptomycin of gentamicin-induced experimental nephrotoxicity","volume":"38","author":"Thibault","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.exer.2017.01.001_bib109","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1586\/17469899.2015.1033403","article-title":"Usher syndrome: a review of the clinical phenotype, genes and therapeutic strategies","volume":"10","author":"Toms","year":"2015","journal-title":"Expert Rev. Ophthalmol."},{"issue":"3","key":"10.1016\/j.exer.2017.01.001_bib110","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ymthe.2006.04.011","article-title":"Specific inhibition of nonsense-mediated mRNA decay components, SMG-1 or Upf1, rescues the phenotype of Ullrich disease fibroblasts","volume":"14","author":"Usuki","year":"2006","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.exer.2017.01.001_bib111","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/bip.10414","article-title":"Molecular recognition of aminoglycoside antibiotics by ribosomal RNA and resistance enzymes: an analysis of x-ray crystal structures","volume":"70","author":"Vicens","year":"2003","journal-title":"Biopolymers"},{"issue":"6","key":"10.1016\/j.exer.2017.01.001_bib112","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ana.1023","article-title":"Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations","volume":"49","author":"Wagner","year":"2001","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.exer.2017.01.001_bib113","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/emboj\/20.4.880","article-title":"The role of Upf proteins in modulating the translation read-through of nonsense-containing transcripts","volume":"20","author":"Wang","year":"2001","journal-title":"EMBO J."},{"issue":"1","key":"10.1016\/j.exer.2017.01.001_bib114","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bbadis.2016.10.018","article-title":"A\u00a0mouse model of aniridia reveals the in\u00a0vivo downstream targets of Pax6 driving iris and ciliary body development in the eye","volume":"1863","author":"Wang","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"issue":"7140","key":"10.1016\/j.exer.2017.01.001_bib115","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 targets genetic disorders caused by nonsense mutations","volume":"447","author":"Welch","year":"2007","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.exer.2017.01.001_bib116","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1183\/09031936.00120910","article-title":"Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis","volume":"38","author":"Wilschanski","year":"2011","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.exer.2017.01.001_bib117","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1165\/rcmb.2013-0282OC","article-title":"Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor","volume":"50","author":"Xue","year":"2014","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.exer.2017.01.001_bib118","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2350-15-6","article-title":"A\u00a0novel MIP gene mutation associated with autosomal dominant congenital cataracts in a Chinese family","volume":"15","author":"Yu","year":"2014","journal-title":"BMC Med. Genet."},{"issue":"16","key":"10.1016\/j.exer.2017.01.001_bib119","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1002\/j.1460-2075.1995.tb00078.x","article-title":"Termination of translation in eukaryotes is governed by two interacting polypeptide chain release factors, eRF1 and eRF3","volume":"14","author":"Zhouravleva","year":"1995","journal-title":"Embo J."}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483517300076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483517300076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T02:31:55Z","timestamp":1749868315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014483517300076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":118,"alternative-id":["S0014483517300076"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2017.01.001","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanism and evidence of nonsense suppression therapy for genetic eye disorders","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2017.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}